| First Author | Cano F | Year | 2008 |
| Journal | Mol Cancer Ther | Volume | 7 |
| Issue | 3 | Pages | 730-5 |
| PubMed ID | 18347158 | Mgi Jnum | J:145377 |
| Mgi Id | MGI:3834496 | Doi | 10.1158/1535-7163.MCT-07-2032 |
| Citation | Cano F, et al. (2008) Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias. Mol Cancer Ther 7(3):730-5 |
| abstractText | Mouse models of human cancer are a potential preclinical setting for drug testing and for development of methods for delivery of macromolecular drugs to tumors. We have assessed a mouse model of leukemia caused by Mll-Enl protein fusion as a preclinical situation in which myeloid-lineage leukemia results from de novo occurrence of chromosomal translocations between Mll and Enl genes. Here, we show that the mouse leukemias respond to cytosine arabinoside, a frontline treatment for human leukemia. The observations show that the myeloid cells are susceptible to the drug and the mice undergo a remission that comprises a reduction of the myeloid population of cells and recovery of the lymphoid population. This translocator model should therefore prove useful for future drug assessments against the recurrent mixed-lineage leukemia-associated translocations. |
